ICON Sponsors Industry-Wide Clinical Trials Survey to Support Transforming Trials Initiative
09 Mai 2018 - 1:00PM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and
medical device industries, today announced the results from a new
survey of pharmaceutical executives and professionals by ICON and
Pharma Intelligence, which examines the key challenge of declining
research and development (R&D) efficiency.
A roundtable of pharmaceutical industry executives discussed the
survey findings, alongside the key challenges affecting the
pharmaceutical industry. The discussion enabled industry experts to
identify the potential for generating savings and improving trial
efficiency, as well as assessing how digital disruption is forcing
change.
The challenges most frequently cited by survey respondents are
patient enrolment (56%), site start-up (43%) and regulatory
approval delays and changes (43%). Respondents also identified
study start up, patient recruitment and retention, and protocol
development as three key areas with the most potential for
generating savings and efficiencies.
“ICON recognizes the challenges our customers are facing and is
focused on building our integrated site and patient network to
improve trial start up, as well as patient recruitment and
retention.” commented Dr. Steve Cutler, Chief Executive Officer,
ICON, on the survey findings.
Opinions of which technology trends will have the greatest
impact on clinical trial operations varied. 36% of survey
respondents noted that leveraging big data and AI technologies
would have the most impact on improving clinical trial efficiency.
35% reported that risk-based approaches toward monitoring held
greater opportunity for impact on clinical development.
The survey demonstrates that industry have realised the need for
a holistic effort to transform trials, however, only one in five
survey respondents (22%) stated their organisation currently has an
integrated effort to drive clinical trials transformations. A
further 83% of respondents believe strategic partnerships with CROs
will be important to the success of clinical trials over the next
five years.
Informed by the survey responses, the Improving Pharma R&D
Efficiency whitepaper proposes a three-part framework for guiding
strategy in transforming clinical trials.
- Adopting a radical patient focus;
- A greater use of adaptive clinical
trials and other alternate trial models;
- Automating data collection and
analysis
The whitepaper argues that while adopting disparate tactics can
improve elements of clinical trial efficiency, the potential is
even greater when change is applied in a coordinated fashion to
reimagine and reinvent the R&D enterprise.
For further information on ICON’s Transforming Trials initiative
and the Improving Pharma R&D Efficiency whitepaper, please
visit: www.iconplc.com/pharma
About the ICON Transforming Trials survey
Designed, conducted and analysed by Informa Engage using
accepted market research methods, 76 members of the Pharma Database
responded to the emailed survey between Oct 16 and 30, 2017. Half
of respondents were director level or higher, 24 percent managers
and 26 percent clinical trial professional personnel with no direct
reports. A roundtable of invited pharmaceutical industry executives
was held at Informa offices in London in November 2017 to discuss
the survey results. The survey data, and roundtable discussion,
were complimented by extensive desk research, in part conducted by
ISR Research.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,380 employees. More information is at
http://www.iconplc.com/wearables
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180509005574/en/
ICON Media ContactOlivia PimentaWeber Shandwick+44 (0)207
067 0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024